JP2016538271A - 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物 - Google Patents
皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物 Download PDFInfo
- Publication number
- JP2016538271A JP2016538271A JP2016526337A JP2016526337A JP2016538271A JP 2016538271 A JP2016538271 A JP 2016538271A JP 2016526337 A JP2016526337 A JP 2016526337A JP 2016526337 A JP2016526337 A JP 2016526337A JP 2016538271 A JP2016538271 A JP 2016538271A
- Authority
- JP
- Japan
- Prior art keywords
- nicotinamide riboside
- salt
- skin
- compound
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000020956 nicotinamide riboside Nutrition 0.000 title claims abstract description 125
- 239000011618 nicotinamide riboside Substances 0.000 title claims abstract description 124
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 title claims abstract description 107
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 230000000699 topical effect Effects 0.000 title claims description 11
- 238000000034 method Methods 0.000 claims abstract description 56
- 150000003839 salts Chemical class 0.000 claims abstract description 50
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 210000004027 cell Anatomy 0.000 claims description 82
- 210000003491 skin Anatomy 0.000 claims description 61
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- -1 nicotinamide riboside compound Chemical class 0.000 claims description 19
- 230000001404 mediated effect Effects 0.000 claims description 17
- 230000005778 DNA damage Effects 0.000 claims description 16
- 231100000277 DNA damage Toxicity 0.000 claims description 15
- 108091093078 Pyrimidine dimer Proteins 0.000 claims description 14
- 230000004224 protection Effects 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 12
- 210000004927 skin cell Anatomy 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 11
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 claims description 9
- 230000004792 oxidative damage Effects 0.000 claims description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 8
- 230000030833 cell death Effects 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 150000003841 chloride salts Chemical class 0.000 claims description 5
- UPUOLJWYFICKJI-UHFFFAOYSA-N cyclobutane;pyrimidine Chemical class C1CCC1.C1=CN=CN=C1 UPUOLJWYFICKJI-UHFFFAOYSA-N 0.000 claims description 5
- 230000001120 cytoprotective effect Effects 0.000 claims description 5
- 239000001177 diphosphate Substances 0.000 claims description 5
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 5
- 235000011180 diphosphates Nutrition 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 235000021317 phosphate Nutrition 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 4
- 229910002651 NO3 Inorganic materials 0.000 claims description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 4
- 229940072107 ascorbate Drugs 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 229940050410 gluconate Drugs 0.000 claims description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 4
- 229940001447 lactate Drugs 0.000 claims description 4
- 229940102396 methyl bromide Drugs 0.000 claims description 4
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- 229940044170 formate Drugs 0.000 claims description 3
- 230000002633 protecting effect Effects 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 150000004675 formic acid derivatives Chemical class 0.000 claims description 2
- 230000004899 motility Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 3
- 230000001767 chemoprotection Effects 0.000 claims 2
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims 1
- 206010072170 Skin wound Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 1
- CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 claims 1
- 150000003893 lactate salts Chemical class 0.000 claims 1
- 150000005451 methyl sulfates Chemical class 0.000 claims 1
- 150000002823 nitrates Chemical class 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 150000003890 succinate salts Chemical class 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
- 230000032683 aging Effects 0.000 abstract description 16
- 239000002537 cosmetic Substances 0.000 abstract description 11
- 230000003834 intracellular effect Effects 0.000 abstract description 6
- 230000004083 survival effect Effects 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 abstract 1
- 206010040840 Skin erosion Diseases 0.000 abstract 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 34
- 229950006238 nadide Drugs 0.000 description 34
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 27
- 239000012091 fetal bovine serum Substances 0.000 description 27
- 208000027418 Wounds and injury Diseases 0.000 description 25
- 206010052428 Wound Diseases 0.000 description 23
- 230000004888 barrier function Effects 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 206010040954 Skin wrinkling Diseases 0.000 description 13
- 230000037303 wrinkles Effects 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000006378 damage Effects 0.000 description 11
- 206010020649 Hyperkeratosis Diseases 0.000 description 10
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 10
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 10
- 102000011990 Sirtuin Human genes 0.000 description 10
- 108050002485 Sirtuin Proteins 0.000 description 10
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 9
- 210000002615 epidermis Anatomy 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 230000005855 radiation Effects 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 230000033616 DNA repair Effects 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001738 genotoxic effect Effects 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 150000003436 stilbenoids Chemical class 0.000 description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 231100000025 genetic toxicology Toxicity 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 235000005152 nicotinamide Nutrition 0.000 description 6
- 239000011570 nicotinamide Substances 0.000 description 6
- 229960003966 nicotinamide Drugs 0.000 description 6
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000001126 Keratosis Diseases 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 206010040799 Skin atrophy Diseases 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 5
- 230000011382 collagen catabolic process Effects 0.000 description 5
- 238000002845 discoloration Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 208000000069 hyperpigmentation Diseases 0.000 description 5
- 230000003810 hyperpigmentation Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 238000007665 sagging Methods 0.000 description 5
- 230000008591 skin barrier function Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000012049 topical pharmaceutical composition Substances 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 238000004383 yellowing Methods 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 206010014970 Ephelides Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 201000004700 rosacea Diseases 0.000 description 4
- 230000036558 skin tension Effects 0.000 description 4
- YABIFCKURFRPPO-IVOJBTPCSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide;chloride Chemical compound [Cl-].NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 YABIFCKURFRPPO-IVOJBTPCSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 239000004342 Benzoyl peroxide Substances 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- 208000035484 Cellulite Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- PUEDDPCUCPRQNY-ZYUZMQFOSA-N D-ribosylnicotinate Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1[N+]1=CC=CC(C([O-])=O)=C1 PUEDDPCUCPRQNY-ZYUZMQFOSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 239000002211 L-ascorbic acid Substances 0.000 description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010024137 Nicotinamide-Nucleotide Adenylyltransferase Proteins 0.000 description 3
- 102000015597 Nicotinamide-nucleotide adenylyltransferase Human genes 0.000 description 3
- 206010049752 Peau d'orange Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 235000010208 anthocyanin Nutrition 0.000 description 3
- 239000004410 anthocyanin Substances 0.000 description 3
- 229930002877 anthocyanin Natural products 0.000 description 3
- 150000004636 anthocyanins Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 description 3
- 229960003328 benzoyl peroxide Drugs 0.000 description 3
- 230000009087 cell motility Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000036232 cellulite Effects 0.000 description 3
- 230000002113 chemopreventative effect Effects 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- SRNWOUGRCWSEMX-UHFFFAOYSA-N Adenosine diphosphate ribose Natural products C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OCC1OC(O)C(O)C1O SRNWOUGRCWSEMX-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010040829 Skin discolouration Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000020934 caloric restriction Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 150000002222 fluorine compounds Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- MAKBMGXNXXXBFE-TURQNECASA-N 1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 MAKBMGXNXXXBFE-TURQNECASA-N 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020005124 DNA Adducts Proteins 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000003656 Electric Burns Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000996052 Homo sapiens Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
- 102100034451 Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Human genes 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 108091026813 Poly(ADPribose) Proteins 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 description 1
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 1
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000007960 cellular response to stress Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- YTMNONATNXDQJF-UBNZBFALSA-N chrysanthemin Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 YTMNONATNXDQJF-UBNZBFALSA-N 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002514 epidermal stem cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 125000005639 glycero group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007512 neuronal protection Effects 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- JOUIQRNQJGXQDC-ZYUZMQFOSA-L nicotinate D-ribonucleotide(2-) Chemical compound O1[C@H](COP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1[N+]1=CC=CC(C([O-])=O)=C1 JOUIQRNQJGXQDC-ZYUZMQFOSA-L 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000006934 radiodermatitis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000008223 ribosides Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000009221 stress response pathway Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Birds (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Cosmetics (AREA)
Abstract
Description
紫外(UV)光は、老化から癌へ及ぶ非常に多くの皮膚の病気の発症において欠くことのできない役割を果たす。数十年に及ぶ少なからぬ証拠は、UV線が、複数の独立した細胞応答を引き起こすことを最終的に実証した。UV線は皮膚を貫通し、そこでタンパク質、脂質、およびDNAによって吸収されて、細胞構造および細胞の機能の進行性劣化を引き起こす一連の事象を生じさせることが知られている(Valacchi,et al.,“Cutaneous responses to environmental stressors”,Ann.N.Y.Acad.Sci.(2012)1271:75−81)。DNAは生命の構成単位であり、その安定性はすべての生きている細胞の適正な機能にとって最も重要である。UV線は、変異原性かつ細胞毒性のDNA損傷、中でも最も注目すべきはシクロブタン−ピリミジン二量体(CPD)および6−4光産物(64pps)を生じさせることによって広範囲の細胞障害を引き起こす可能性のある最も強力な(また一般的な)環境因子の1つである(Narayanan,et al.,“Ultraviolet radiation and skin cancer”,Int.J.Dermatol.(2010)49:978−86)。UV介在性のDNA損傷が多くの増殖性細胞障害における早期の事象であることに注目することが重要である。UV誘導性DNA損傷の2つの主要な種類は、CPDおよび64pp(ならびにそれらのデューア異性体)である(Sinha,R.P.およびHader,D.P.,“UV−induced DNA damage and repair:a review”,Photochem.Photobiol.Sci.(2002)1:225−36、およびRastogi,et al.,“Molecular mechanism of ultraviolet radiation−induced DNA damage and repair”,J.Nucleic Acids(2010)2010:592980)。修復されない場合、これらの多くのDNA損傷はDNAの複製を妨げ、続いてDNAの突然変異を引き起こす可能性がある。したがってこれらの損傷は変異原性である(場合によっては増殖性疾患につながる)可能性があり、かつ/または細胞毒性である(細胞死を引き起こす)可能性がある。64ppは、CPDの頻度の約3分の1で起こるが、それらはより変異原性である(Sinha&Hader,2002)。一実施形態では、これらのUV介在性のDNA付加物の防止は、老化から癌へ及ぶ数種類の増殖性疾患の発病を防ぐことに優先する。
生命体と環境との間に水を通さないバリアを維持することが、皮膚の不可欠な機能である。このバリア機能は、その生命体の死につながる可能性のある脱水を防止するのに役立つ(Jiang,S.J.,et al.,“Ultraviolet B−induced alterations of the skin barrier and epidermal calcium gradient”,Exp.Dermatol.(2007)16:985−992)。UV光が線量依存的に表皮の皮膚バリア機能を乱すことが実証されている(Haratake,A,et al.,“UVB−induced alterations in permeability barrier function:roles for epidermal hyperproliferation and thymocyte−mediated response”,J.Invest.Dermatol.(1997)108:769−775、および先行引用文献)。皮膚バリア機能障害は、皮膚の水分量の尺度である経表皮水分蒸散量(Transepidermal Water Loss)(TEWL)を測定することによって直接に評価することができる(Oba、C.,et al.,“Collagen hydrolysate intake improves the loss of epidermal barrier function and skin elasticity induced by UVB irradiation in hairless mice”,Photodermatol.Photoimmunol.Photomed.(2013)29:204−11、および先行引用文献)。
これら化合物は、これらに限定されないが経口、舌下、口内、目、肺、直腸、および非経口投与を含めた任意の経路によって、あるいは口腔または鼻腔スプレー(例えば、霧状蒸気、液滴、または固体粒子の吸入)として投与することができる。非経口投与には、例えば静脈内、筋内、動脈内、腹膜内、鼻腔内、膣内、膀胱腔内(例えば膀胱へ)、皮内、経皮、局所、または皮下投与が挙げられる。また本発明の範囲内では、薬物の全身的または局所的放出が後に起こるコントロール製剤(controlled formulation)での患者の体内へのNRの点滴注入も考えられる。例えば、循環させるためにこの薬物を制御放出用のデポー製剤中に局在化させることができる。
一実施形態では、NRは、化合物および/または医薬製品の経皮送達のための媒体として使用される。
或る実施形態では、NRは、プテロスチルベンと組み合わせて、任意選択でさらにクルクミンと組み合わせて使用される。
或る実施形態では、NRは、1種類または複数種類のスチルベノイド(すなわちスチルベン化合物)と組み合わせて使用される。スチルベノイドの実例は、別の用途の場合ではあるが、Josephらの米国特許出願公開第2009/0069444号明細書(参照により本明細書に援用される)中で考察されている。
一実施形態では、NRは、化合物および/または医薬製品もしくは調合物の経皮送達を向上させるために1種類または複数種類のペプチドと組み合わせて使用される。
一実施形態では、NRは、1種類または複数種類のレチノール、サリチル酸、過酸化ベンゾイル、またはビタミンC(L−アスコルビン酸)と組み合わせて、にきび、酒さ、角化症、乾癬、皮膚炎などから選択される皮膚の状態を治療するために使用される。
ヒトの皮膚細胞の酸化損傷を防止するNR処理である。
ヒトの皮膚細胞において有害なUV−C介在性の損傷を防止するNR処理である。
マウスの皮膚細胞中における細胞の成長および遊走を促進させるNR処理である。
マウスの皮膚細胞において細胞の成長および遊走を促進させるNR処理である。
ヒト皮膚細胞における有害なUV介在性の損傷を防止するNR処理である。
Claims (22)
- 個体の皮膚におけるUV介在性のDNA損傷を治療または予防するための化学保護方法において、そのような治療を必要とする前記個体に化合物ニコチンアミドリボシドまたはその塩の治療に有効な量を局所的に投与することを含むことを特徴とする、方法。
- 請求項1に記載の化学保護方法において、前記個体がヒトであることを特徴とする、方法。
- 請求項2に記載の化学保護方法において、前記ニコチンアミドリボシド化合物またはその塩が、薬学的に許容できる担体を含む組成物の状態で提供されることを特徴とする、方法。
- 請求項3に記載の化学保護方法において、前記ニコチンアミドリボシド化合物が、フッ化物、塩化物、臭化物、ヨウ化物、ギ酸塩、酢酸塩、アスコルビン酸塩、安息香酸塩、炭酸塩、クエン酸塩、カルバミン酸塩、ギ酸塩、グルコン酸塩、乳酸塩、メチル臭化物、メチル硫酸塩、硝酸塩、リン酸塩、二リン酸塩、コハク酸塩、硫酸塩、およびトリフルオロ酢酸塩からなる群から選択される塩であることを特徴とする、方法。
- 請求項4に記載の化学保護方法において、前記ニコチンアミドリボシド化合物が塩化物塩であることを特徴とする、方法。
- 請求項3に記載の化学保護方法において、総薬用量としての前記ニコチンアミドリボシド化合物またはその塩の治療に有効な量が、前記組成物の総重量を基準にして約0.01重量%〜約50重量%の範囲であることを特徴とする、方法。
- 請求項3に記載の化学保護方法において、総薬用量としての前記ニコチンアミドリボシド化合物またはその塩の治療に有効な量が、前記組成物の総重量を基準にして約0.1重量%〜約10重量%の範囲であることを特徴とする、方法。
- 請求項1に記載の化学保護方法において、シクロブタン−ピリミジン二量体(CPD)または6−4光産物(64pps)の形成によって示されるDNA損傷が、約10%超減少することを特徴とする、方法。
- 個体の皮膚の酸化損傷を治療または予防するための細胞保護方法において、そのような治療を必要とする前記個体に化合物ニコチンアミドリボシドまたはその塩の治療に有効な量を局所的に投与することを含むことを特徴とする、方法。
- 請求項9に記載の細胞保護方法において、前記個体がヒトであることを特徴とする、方法。
- 請求項10に記載の細胞保護方法において、前記ニコチンアミドリボシド化合物またはその塩が、薬学的に許容できる担体を含む組成物の状態で提供されることを特徴とする、方法。
- 請求項11に記載の細胞保護方法において、前記ニコチンアミドリボシド化合物が、フッ化物、塩化物、臭化物、ヨウ化物、ギ酸塩、酢酸塩、アスコルビン酸塩、安息香酸塩、炭酸塩、クエン酸塩、カルバミン酸塩、ギ酸塩、グルコン酸塩、乳酸塩、メチル臭化物、メチル硫酸塩、硝酸塩、リン酸塩、二リン酸塩、コハク酸塩、硫酸塩、およびトリフルオロ酢酸塩からなる群から選択される塩であることを特徴とする、方法。
- 請求項12に記載の細胞保護方法において、前記ニコチンアミドリボシド化合物が塩化物塩であることを特徴とする、方法。
- 請求項11に記載の細胞保護方法において、総薬用量としての前記ニコチンアミドリボシド化合物またはその塩の治療に有効な量が、前記組成物の総重量を基準にして約0.01重量%〜約50重量%の範囲であることを特徴とする、方法。
- 請求項11に記載の細胞保護方法において、総薬用量としての前記ニコチンアミドリボシド化合物またはその塩の治療に有効な量が、前記組成物の総重量を基準にして約0.1重量%〜約10重量%の範囲であることを特徴とする、方法。
- 請求項9に記載の細胞保護方法において、細胞死が約10%超減少することを特徴とする、方法。
- 個体の皮膚の創傷を治療または修復するための方法において、そのような治療を必要とする前記個体に化合物ニコチンアミドリボシドまたはその塩の治療に有効な量を局所的に投与することを含み、前記皮膚中の皮膚細胞が高い運動性および/または増殖を有することを特徴とする、方法。
- 請求項17に記載の方法において、前記個体がヒトであることを特徴とする、方法。
- 請求項18に記載の方法において、前記ニコチンアミドリボシド化合物またはその塩が、薬学的に許容できる担体を含む組成物の状態で提供されることを特徴とする、方法。
- 請求項19に記載の方法において、前記ニコチンアミドリボシド化合物が、フッ化物、塩化物、臭化物、ヨウ化物、ギ酸塩、酢酸塩、アスコルビン酸塩、安息香酸塩、炭酸塩、クエン酸塩、カルバミン酸塩、ギ酸塩、グルコン酸塩、乳酸塩、メチル臭化物、メチル硫酸塩、硝酸塩、リン酸塩、二リン酸塩、コハク酸塩、硫酸塩、およびトリフルオロ酢酸塩からなる群から選択される塩であることを特徴とする、方法。
- 請求項20に記載の方法において、前記ニコチンアミドリボシド化合物が塩化物塩であることを特徴とする、方法。
- 請求項19に記載の方法において、総薬用量としての前記ニコチンアミドリボシド化合物またはその塩の治療に有効な量が、前記組成物の総重量を基準にして約0.01重量%〜約50重量%の範囲であることを特徴とする、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361897713P | 2013-10-30 | 2013-10-30 | |
US61/897,713 | 2013-10-30 | ||
PCT/US2014/063260 WO2015066382A1 (en) | 2013-10-30 | 2014-10-30 | Nicotinamide riboside compositions for topical use in treating skin conditions |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016538271A true JP2016538271A (ja) | 2016-12-08 |
JP2016538271A5 JP2016538271A5 (ja) | 2017-12-21 |
JP6509844B2 JP6509844B2 (ja) | 2019-05-08 |
Family
ID=53005146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016526337A Active JP6509844B2 (ja) | 2013-10-30 | 2014-10-30 | 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物 |
Country Status (12)
Country | Link |
---|---|
US (2) | US10688118B2 (ja) |
EP (1) | EP3063163B1 (ja) |
JP (1) | JP6509844B2 (ja) |
KR (3) | KR20160067195A (ja) |
CN (2) | CN109985056A (ja) |
AU (1) | AU2014342185B2 (ja) |
CA (1) | CA2928656C (ja) |
ES (1) | ES2925879T3 (ja) |
MX (2) | MX2021009652A (ja) |
NZ (1) | NZ719328A (ja) |
WO (1) | WO2015066382A1 (ja) |
ZA (1) | ZA201603314B (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017518306A (ja) * | 2014-06-02 | 2017-07-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | 結晶性β−D−ニコチンアミドリボシドの製造および使用 |
JP2018517774A (ja) * | 2015-06-10 | 2018-07-05 | エリジウム・ヘルス・インコーポレイテッド | ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法 |
JP2020536624A (ja) * | 2017-10-06 | 2020-12-17 | イクソバダーム リミテッドXobaderm Limited | 皮膚に活性化合物を供与するキット |
JP2023510034A (ja) * | 2020-04-03 | 2023-03-10 | 深▲せん▼市迪克曼科技開発有限公司 | ニコチンアミドリボースの有機酸塩、その組成物及び製造方法 |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6559713B2 (ja) | 2014-06-06 | 2019-08-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | ニコチンアミドリボシド類似体ならびにその医薬組成物および使用 |
CN106715454B (zh) | 2014-07-24 | 2020-06-16 | 格雷斯公司 | 烟酰胺核苷的结晶形式 |
US10189872B2 (en) | 2015-03-09 | 2019-01-29 | W. R. Grace & Co.-Conn | Crystalline form of nicotinamide riboside |
WO2016149395A1 (en) | 2015-03-16 | 2016-09-22 | ChromaDex Inc. | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof |
EP3288529A1 (en) | 2015-05-01 | 2018-03-07 | The Procter and Gamble Company | Method of improving the appearance of skin and compositions therefor using nicotinamide riboside |
JP2018515485A (ja) | 2015-05-01 | 2018-06-14 | ザ プロクター アンド ギャンブル カンパニー | 皮膚の外観を改善する方法及びニコチンアミドリボシドを使用したそのための組成物 |
US20160317419A1 (en) * | 2015-05-01 | 2016-11-03 | The Procter & Gamble Company | Method of improving skin health and compositions therefor |
WO2016210232A1 (en) * | 2015-06-25 | 2016-12-29 | N.V. Perricone Llc | Niacinamide mononucleotide formulations for skin aging |
WO2017004102A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container |
US20160374918A1 (en) * | 2015-06-29 | 2016-12-29 | The Procter & Gamble Company | Encapsulated skin care agent |
US20160374908A1 (en) | 2015-06-29 | 2016-12-29 | The Procter & Gamble Company | Skin care composition and methods of using the same |
KR102114892B1 (ko) | 2016-01-11 | 2020-05-26 | 더 프록터 앤드 갬블 캄파니 | 피부 상태의 치료 방법 및 그를 위한 조성물 |
US10000520B2 (en) | 2016-03-16 | 2018-06-19 | ChromaDex Inc. | B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof |
US10183036B2 (en) * | 2016-04-20 | 2019-01-22 | ChromaDex Inc. | Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors |
CN109982706A (zh) * | 2016-08-22 | 2019-07-05 | 益力舒健康公司 | 用于治疗神经退行性病症的烟酰胺核苷和紫檀芪的组合物和方法 |
WO2018089830A1 (en) | 2016-11-11 | 2018-05-17 | The Queen's University Of Belfast | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
MX2019006278A (es) | 2016-11-29 | 2019-08-21 | Univ Iowa Res Found | Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia. |
CA3047215A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions with cystine |
US11260005B2 (en) | 2016-12-21 | 2022-03-01 | Conopco, Inc. | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids |
EA038885B1 (ru) | 2016-12-21 | 2021-11-02 | ЮНИЛЕВЕР АйПи ХОЛДИНГС Б.В. | Осветляющая кожу добавка для местного применения и композиция с аминокислотами и никотинамидными соединениями |
EP3558243B1 (en) | 2016-12-21 | 2022-10-05 | Unilever IP Holdings B.V. | Personal care compositions comprising poorly soluble compounds |
RU2651047C1 (ru) * | 2017-05-04 | 2018-04-18 | Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" | Лекарственная композиция цитопротекторного действия и способ ее получения |
EP3624808A4 (en) * | 2017-05-18 | 2021-03-03 | Elysium Health, Inc. | PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP |
SG11201912267SA (en) | 2017-06-19 | 2020-01-30 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
EP3641725A1 (en) | 2017-06-23 | 2020-04-29 | The Procter and Gamble Company | Composition and method for improving the appearance of skin |
US11364187B2 (en) | 2017-07-28 | 2022-06-21 | Centers For Age Control, Inc. | Compositions and methods for preventing and reversing aspects of aging |
JP7210459B2 (ja) * | 2017-09-14 | 2023-01-23 | めぐみ 田中 | 老化防止剤及び老化防止方法 |
EP3727400A4 (en) | 2017-12-22 | 2021-10-20 | Elysium Health, Inc. | CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE |
CN112437657A (zh) | 2018-07-03 | 2021-03-02 | 宝洁公司 | 处理皮肤状况的方法 |
CN110913864B (zh) * | 2018-08-17 | 2022-12-13 | 邦泰生物工程(深圳)有限公司 | 一种稳定型烟酰胺核糖组合物及其制备方法 |
KR102060374B1 (ko) * | 2018-12-14 | 2019-12-30 | 주식회사 휴메딕스 | 지방알코올 컨쥬게이션된 니코틴아미드 리보사이드 유도체 |
WO2020131578A2 (en) | 2018-12-17 | 2020-06-25 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
CN114423771A (zh) * | 2019-07-19 | 2022-04-29 | 生物合成股份公司 | 制备烟酰胺呋喃核糖苷盐的方法、烟酰胺呋喃核糖苷盐本身及其用途 |
CN110638827A (zh) * | 2019-10-17 | 2020-01-03 | 泓博元生命科技(深圳)有限公司 | Nadh及其盐在制备皮肤色素抑制剂中的应用 |
CN111166760A (zh) * | 2019-12-17 | 2020-05-19 | 浙江安赛新材料科技有限公司 | β-烟酰胺单核苷酸或其前体的组合物及制备方法、应用 |
KR102315139B1 (ko) | 2019-12-17 | 2021-10-20 | 주식회사 휴메딕스 | 지방아민 컨쥬게이션된 니코틴아미드 리보사이드 유도체 |
CN111184732B (zh) * | 2020-03-04 | 2023-09-08 | 武汉华纳联合药业有限公司 | 一种复合组合物制剂及其制备方法和皮肤炎症中的应用 |
FR3110410A1 (fr) * | 2020-05-20 | 2021-11-26 | Nuvamid Sa | Compositions cosmétiques anti-âge comprenant de la NMN |
US20230210746A1 (en) * | 2020-05-20 | 2023-07-06 | Nuvamid Sa | Anti-aging cosmetic compositions comprising nmn |
EP4157206A1 (en) | 2020-06-01 | 2023-04-05 | The Procter & Gamble Company | Method of improving penetration of a vitamin b3 compound into skin |
US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
CN111632049A (zh) * | 2020-06-09 | 2020-09-08 | 西北农林科技大学 | 一种通过综合矫正细胞活性氧簇代谢紊乱以缓解睾丸衰老损伤的复合配方 |
WO2022047182A1 (en) * | 2020-08-28 | 2022-03-03 | University Of Washington | High dose nicotinamide adenine dinucleotide (nad) precursor regimens for reduction of inflammation in human patients with preexisting inflammation |
WO2022234336A1 (en) * | 2021-05-04 | 2022-11-10 | Sovida Solutions Ltd. | Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof |
CN114129509B (zh) * | 2021-12-03 | 2023-12-01 | 药酚享科技(北京)有限公司 | 一种保湿性nmn亲水凝胶剂及其制备方法 |
CN114933621A (zh) * | 2022-04-13 | 2022-08-23 | 深圳市迪克曼生物科技有限公司 | 烟酰胺核糖的有机酸盐及其结晶形态、制备方法与用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008529502A (ja) * | 2005-02-08 | 2008-08-07 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物 |
US20120172584A1 (en) * | 2005-11-18 | 2012-07-05 | Cornell University | Nicotyl riboside compositions and methods of use |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100369602C (zh) * | 2001-02-22 | 2008-02-20 | 荷兰联合利华有限公司 | 改进的皮肤用组合物 |
WO2005077091A2 (en) | 2004-02-10 | 2005-08-25 | Trustees Of Dartmouth College | Nicotinamide riboside kinase compositions and methods for using the same |
PT1755391E (pt) | 2004-06-04 | 2016-02-03 | Univ Washington | Métodos e composições para o tratamento de neuropatias |
WO2006105440A2 (en) | 2005-03-30 | 2006-10-05 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
JP2009500357A (ja) * | 2005-07-07 | 2009-01-08 | サートリス ファーマシューティカルズ, インコーポレイテッド | 肥満、インスリン抵抗性障害およびミトコンドリア関連障害を処置または予防するための方法および関連する組成物 |
CN101257897A (zh) * | 2005-07-07 | 2008-09-03 | 西特里斯药业公司 | 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物 |
JP2010520897A (ja) * | 2007-03-12 | 2010-06-17 | ディーエスエム アイピー アセッツ ビー.ブイ. | 化粧品組成物 |
US20090069444A1 (en) | 2007-09-07 | 2009-03-12 | The United States Of America, As Represented By Th E Secretary Of Agriculture | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration |
WO2011083738A1 (ja) * | 2010-01-06 | 2011-07-14 | 株式会社ヤクルト本社 | 経口用のdna損傷修復促進剤及びエラスターゼ活性抑制剤 |
-
2014
- 2014-10-30 NZ NZ719328A patent/NZ719328A/en unknown
- 2014-10-30 ES ES14857903T patent/ES2925879T3/es active Active
- 2014-10-30 CN CN201910027571.7A patent/CN109985056A/zh active Pending
- 2014-10-30 KR KR1020167014302A patent/KR20160067195A/ko not_active IP Right Cessation
- 2014-10-30 CN CN201480071722.4A patent/CN105873937A/zh active Pending
- 2014-10-30 WO PCT/US2014/063260 patent/WO2015066382A1/en active Application Filing
- 2014-10-30 AU AU2014342185A patent/AU2014342185B2/en active Active
- 2014-10-30 CA CA2928656A patent/CA2928656C/en active Active
- 2014-10-30 MX MX2021009652A patent/MX2021009652A/es unknown
- 2014-10-30 EP EP14857903.0A patent/EP3063163B1/en active Active
- 2014-10-30 US US15/033,285 patent/US10688118B2/en active Active
- 2014-10-30 JP JP2016526337A patent/JP6509844B2/ja active Active
- 2014-10-30 MX MX2016005574A patent/MX2016005574A/es unknown
- 2014-10-30 KR KR1020217026414A patent/KR20210107895A/ko active Application Filing
- 2014-10-30 KR KR1020227022241A patent/KR20220098049A/ko not_active Application Discontinuation
-
2016
- 2016-05-16 ZA ZA2016/03314A patent/ZA201603314B/en unknown
-
2020
- 2020-06-03 US US16/891,824 patent/US11033568B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008529502A (ja) * | 2005-02-08 | 2008-08-07 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物 |
US20120172584A1 (en) * | 2005-11-18 | 2012-07-05 | Cornell University | Nicotyl riboside compositions and methods of use |
Non-Patent Citations (7)
Title |
---|
ALESSANDRA MOCALI. ET AL.: "Induction, Effects, and Quantification of Sublethal Oxiadtive Stress by Hydrogen Peroxide on Culture", EXPERIMENTAL CELL RESEARCH, vol. 216, JPN6018025162, 1995, pages 388 - 395, ISSN: 0003830709 * |
ANTHONY A. SAUVE: "Pharmaceutical Strategies for Activating Sirtuins", CURRENT PHARMACEUTICAL DESIGN, vol. 15, JPN6018025164, 2009, pages 45 - 56, XP008137980, ISSN: 0003830710, DOI: 10.2174/138161209787185797 * |
BRIGITTE BALARD AND PAOLO U. GIACOMONI: "Nicotinamide adenosine dinucleotide level in demethylsulfate-treated or UV-irradiated mouse epidermi", MUTATION RESEARCH, vol. 219, JPN6018025157, 1989, pages 71 - 79, ISSN: 0003830705 * |
DEVITA SURJANA. ET AL.: "Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in human keratinocytes and", CARCINOGENESIS, vol. 34, no. 5, JPN6018025156, 24 January 2013 (2013-01-24), pages 1144 - 1149, ISSN: 0003830704 * |
FEDERICO LICASTRO AND ROY L. WALFORD: "MODULATORY EFFECT OF NICOTINAMIDE ON UNSCHEDULED DNA SYNTHESIS IN LYMPHOCYTES FROM YOUNG AND OLD MIC", MECHANISMS OF AGEING AND DEVELOPMENT, vol. 35, JPN6018025158, 1986, pages 123 - 131, ISSN: 0003830706 * |
H.A. ROVITO AND J.E. OBLONG: "Nicotinamide preferntially protects glycolysis in dermal fibroblasts under oxidative stress conditio", BRITISHI JOURNAL OF DERMATOLOGY, vol. Vol.169, Suppl.2, JPN6018025160, 4 March 2013 (2013-03-04), pages 15 - 24, ISSN: 0003830707 * |
NOBUMASA HARA. ET AL.: "Nicotinic acid elevattes cellular NAD levels and protects cells against oxidative stress", 生化学, JPN6018025161, 2007, pages 1 - 0269, ISSN: 0003830708 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017518306A (ja) * | 2014-06-02 | 2017-07-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | 結晶性β−D−ニコチンアミドリボシドの製造および使用 |
JP2018517774A (ja) * | 2015-06-10 | 2018-07-05 | エリジウム・ヘルス・インコーポレイテッド | ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法 |
JP2020536624A (ja) * | 2017-10-06 | 2020-12-17 | イクソバダーム リミテッドXobaderm Limited | 皮膚に活性化合物を供与するキット |
JP7188794B2 (ja) | 2017-10-06 | 2022-12-13 | イクソバダーム リミテッド | 皮膚に活性化合物を供与するキット |
JP2023510034A (ja) * | 2020-04-03 | 2023-03-10 | 深▲せん▼市迪克曼科技開発有限公司 | ニコチンアミドリボースの有機酸塩、その組成物及び製造方法 |
JP7319744B2 (ja) | 2020-04-03 | 2023-08-02 | 深▲せん▼市迪克曼科技開発有限公司 | ニコチンアミドリボースの有機酸塩、その組成物及び製造方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20220098049A (ko) | 2022-07-08 |
US10688118B2 (en) | 2020-06-23 |
KR20160067195A (ko) | 2016-06-13 |
EP3063163B1 (en) | 2022-08-10 |
ES2925879T3 (es) | 2022-10-20 |
CA2928656A1 (en) | 2015-05-07 |
MX2021009652A (es) | 2022-07-26 |
WO2015066382A1 (en) | 2015-05-07 |
JP6509844B2 (ja) | 2019-05-08 |
EP3063163A1 (en) | 2016-09-07 |
US20200289536A1 (en) | 2020-09-17 |
KR20210107895A (ko) | 2021-09-01 |
CN105873937A (zh) | 2016-08-17 |
ZA201603314B (en) | 2017-09-27 |
CN109985056A (zh) | 2019-07-09 |
CA2928656C (en) | 2020-07-28 |
NZ719328A (en) | 2022-04-29 |
AU2014342185B2 (en) | 2019-01-03 |
EP3063163A4 (en) | 2017-05-10 |
US11033568B2 (en) | 2021-06-15 |
MX2016005574A (es) | 2016-12-09 |
US20160250241A1 (en) | 2016-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6509844B2 (ja) | 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物 | |
AU2014342185A1 (en) | Nicotinamide riboside compositions for topical use in treating skin conditions | |
TWI257303B (en) | A method for enhancing protective cellular responses to genotoxic stress in skin | |
PT2714010T (pt) | Composição farmacêutica tópica à base de alcanos semifluorados | |
US20200179318A1 (en) | Compositions and Methods for Treating Skin Conditions Using Light and Polycarboxylic Acids | |
JP2017528505A (ja) | 発毛増進、皮膚再生促進及び創傷治癒のための組成物及び方法 | |
US8816065B2 (en) | Pharmaceutical or cosmetic composition containing nicotinic acid adenine dinucleotide phosphate or derivative thereof | |
CN113038920A (zh) | 用于治疗美学皮肤病症的铁螯合化合物 | |
KR20200079502A (ko) | 남성 패턴 대머리를 포함하는 피부학적 장애를 치료하기 위한 국소 제형 | |
US20230372437A1 (en) | Compositions and methods for the treatment of hair loss and other conditions | |
JP2007153863A (ja) | 毛髪改善外用剤 | |
KR20130077644A (ko) | Fgf를 포함하는 피부 재생용 조성물 | |
JP2014508740A (ja) | 治療用冷却剤組成物における溶媒としての使用のための(r)−1,2−プロパンジオール | |
CA3084891A1 (en) | Compositions and methods for treating skin conditions using infrared light and resorcinols | |
JP7396585B2 (ja) | Tslp遺伝子発現抑制用、il-33遺伝子発現抑制用、又はフィラグリン産生促進用組成物 | |
JP2009537491A (ja) | ハイドロキノン、フルオシノロンアセトニド、およびトレチノインの組合せを含む、皮膚の光老化の徴候を治療するための組成物の使用 | |
WO2021148366A1 (fr) | Composition sous une forme adaptée à une administration par voie topique à base de plantes, et procédé de fabrication associé | |
US20190021995A1 (en) | Formulation for treatment of peripheral joints, spinal joints and/or extracellular matrix elements of connective tissue, method of manufacture and uses | |
KR20120032009A (ko) | 피부 수분 투과 기능 이상의 예방제 또는 치료제 | |
PL203478B1 (pl) | Zastosowanie pochodnych biguanidu i ich soli do wytwarzania leku do bliznowacenia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171027 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171027 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180703 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181001 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181130 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190305 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190403 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6509844 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |